Latest Epidermal growth factor receptor Stories
By the time the human genome was mapped, cancer researchers had already begun investigating the proteins that were encoded by these newly identified genes. As the molecular engines that control all functions of the body, scientists wanted to find out how proteins work to promote health, or malfunction to cause disease.
An international clinical trial led by Canadian researchers has demonstrated that a drug called erlotinib increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options.
Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva). Patients with tumors that expressed high levels of epidermal growth factor receptor (EGFR) and low levels of phosphorylated PKB/Akt, an enzyme, responded better to erlotinib than patients with low levels of EGFR expression and high levels of phosphorylated PKB/Akt. The study findings appear in the...
Scientists have uncovered new information about a specific mechanism involved in the biology of malignant human tumor cells. The findings, published in the June issue of Cancer Cell, significantly advance knowledge about epidermal growth factor receptor (EGFR).
Binding gold nanoparticles to a specific antibody for cancer cells could make cancer detection much easier, say medical researchers from the University of California, San Francisco and Georgia Institute of Technology.
- Withering but not falling off, as a blossom that persists on a twig after flowering.